ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.
UK-based ConserV Bioscience Limited believes its mission to develop effective vaccines that protect against endemic and emergent infectious diseases will be greatly boosted through an R&D collaboration with Belgium’s eTheRNA Immunotherapies, focused first on developing an HIV vaccine.
The alliance, announced on 4 March, will focus on development and evaluation of mRNA vaccine formulations against HIV, with the objective of identifying a lead to move forward to clinical development
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
